Patents by Inventor Reiko TODAKA

Reiko TODAKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240390404
    Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R1, R3, and R4 is —OH or —OAc; R2 is a halogen atom, —OH, or —OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.
    Type: Application
    Filed: August 5, 2024
    Publication date: November 28, 2024
    Applicants: KEIO UNIVERSITY, THE KITASATO INSTITUTE
    Inventors: Kazuhiko KATAYAMA, Akira FUJIMOTO, Kei HAGA, Reiko TODAKA, Toshiro SATO
  • Publication number: 20240316181
    Abstract: An object of the present invention is to establish means for providing a component vaccine which can selectively or intensively induce cell-mediated immunity mainly attributable to MHC class I, and humoral immunity mainly attributable to MHC class II. The inventors have found that the object can be attained by providing a component vaccine containing, as an active ingredient, a trimer and/or a hexamer of a molecular needle carrying a peptide binding to MHC class I and/or a peptide binding to MHC class II. The inventors have also found an information acquisition method that can determine the MHC class or the like of a test peptide or a similar substance by detecting a change in secretion of a physiologically active substance such as a cytokine in a test animal which has been infected with a target microorganism.
    Type: Application
    Filed: January 7, 2022
    Publication date: September 26, 2024
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE
    Inventors: Takafumi UENO, Dan Que NGUYEN, Kazuhiko KATAYAMA, Reiko TODAKA, Kei HAGA, Akihito SAWADA
  • Publication number: 20230365659
    Abstract: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.
    Type: Application
    Filed: October 1, 2021
    Publication date: November 16, 2023
    Applicants: EPSILON MOLECULAR ENGINEERING, INC., THE KITASATO INSTITUTE, Kao Corporation
    Inventors: Hidekazu Masaki, Shigefumi KUMACHI, Ryo YONEHARA, Yuta MATSUMURA, Hibiki KAWANO, Takuto TOJO, Takuya MORIMOTO, Kazunhiko KATAYAMA, Kei HAGA, Reiko TODAKA, Akihito SAWADA, Tomomi TAKANO
  • Patent number: 11517616
    Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: December 6, 2022
    Assignees: Denka Company Limited, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Takafumi Ueno, Kengo Yoshikawa, Megumi Mano, Kazuhiko Katayama, Motohiro Miki, Reiko Todaka, Yoshimasa Takahashi, Taishi Onodera
  • Publication number: 20220362370
    Abstract: An object of the present invention is to establish means for providing a component vaccine which can elicit immunity to a non-structural protein. The present inventors have found that the object can be attained by providing a component vaccine containing an associated product containing a trimer and/or a hexamer of a molecular needle to which a non-structural protein of a pathogenic virus is attached.
    Type: Application
    Filed: August 26, 2020
    Publication date: November 17, 2022
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, DENKA COMPANY LIMITED
    Inventors: Takafumi UENO, Dan Que NGUYEN, Kazuhiko KATAYAMA, Reiko TODAKA, Kei HAGA, Akihito SAWADA
  • Patent number: 11299750
    Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 12, 2022
    Assignees: DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Denka Company Limited, NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
    Inventors: Kei Haga, Akira Fujimoto, Reiko Todaka, Kazuhiko Katayama, Akira Nakanishi, Motohiro Miki, Sakari Sekine, Hiroshi Otsuka, Shigetaka Mimori
  • Publication number: 20220062315
    Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising, as an active ingredient, a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT). Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof. [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R4, R3, and R4 is —OH or -OAc; R2 is a halogen atom, —OH, or -OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Applicants: KEIO UNIVERSITY, THE KITASATO INSTITUTE
    Inventors: Kazuhiko KATAYAMA, Akira FUJIMOTO, Kei HAGA, Reiko TODAKA, Toshiro SATO
  • Publication number: 20210299240
    Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].
    Type: Application
    Filed: October 19, 2017
    Publication date: September 30, 2021
    Applicants: DENKA COMPANY LIMITED, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Takafumi UENO, Kengo YOSHIKAWA, Megumi MANO, Kazuhiko KATAYAMA, Motohiro MIKI, Reiko TODAKA, Yoshimasa TAKAHASHI, Taishi ONODERA
  • Publication number: 20190040415
    Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.
    Type: Application
    Filed: February 1, 2017
    Publication date: February 7, 2019
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, DENKA COMPANY LIMITED, NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
    Inventors: Kei HAGA, Akira FUJIMOTO, Reiko TODAKA, Kazuhiko KATAYAMA, Akira NAKANISHI, Motohiro MIKI, Sakari SEKINE, Hiroshi OTSUKA, Shigetaka MIMORI